Symbicort classification

Pro Research Analysisby

Searched over 200M research papers for "symbicort classification"

Analyzed relevant papers

Symbicort Classification: An Overview

Introduction to Symbicort

Symbicort is a combination inhaler used primarily for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It contains two active ingredients: budesonide, a corticosteroid, and formoterol, a long-acting beta-2 agonist (LABA) Halpin2008Chew2012Kuna2002. This combination allows Symbicort to address both inflammation and bronchoconstriction, making it a comprehensive treatment option for respiratory conditions.

Pharmacological Classification of Symbicort

Budesonide: Corticosteroid

Budesonide is a corticosteroid that works by reducing inflammation in the airways. Inflammation is a key component of asthma and COPD, leading to symptoms such as wheezing, shortness of breath, and chest tightness. By decreasing inflammation, budesonide helps to prevent and control these symptoms Halpin2008Kuna2002.

Formoterol: Long-Acting Beta-2 Agonist (LABA)

Formoterol is a long-acting beta-2 agonist that helps to relax the muscles around the airways, making it easier to breathe. It has a rapid onset of action and a long duration of effect, which makes it suitable for both maintenance and relief of symptoms Halpin2008Chew2012Kuna2002.

Clinical Applications and Benefits

Asthma Management

Symbicort is used in various asthma management strategies, including fixed-dose maintenance therapy, adjustable-dose maintenance therapy, and as both maintenance and reliever therapy (SMART) . Studies have shown that Symbicort is more effective than using higher doses of corticosteroids alone and offers better control of asthma symptoms . The SMART approach, in particular, has been found to improve asthma control, reduce exacerbations, and lower both direct and indirect treatment costs compared to fixed maintenance therapy .

COPD Treatment

In COPD, Symbicort provides clinical advantages over using its individual components separately. It helps to improve lung function, reduce symptoms, and enhance the quality of life for patients with COPD, often at little or no extra cost .

Economic Considerations

Pharmacoeconomic studies have demonstrated that Symbicort is cost-effective compared to using separate inhalers for budesonide and formoterol. Adjustable dosing with Symbicort has been associated with lower treatment costs while maintaining effective control of asthma . This economic benefit is significant for both patients and healthcare systems.

Conclusion

Symbicort, containing budesonide and formoterol, is classified as a combination inhaler that addresses both inflammation and bronchoconstriction in asthma and COPD. Its dual-action mechanism, clinical efficacy, and cost-effectiveness make it a valuable option in the management of these chronic respiratory conditions.

Sources and full results

Most relevant research papers on this topic

Symbicort: a pharmacoeconomic review

Symbicort is a cost-effective combination inhaler for asthma and COPD, offering clinical advantages at little or no extra cost compared to separate budesonide and formoterol inhalers.

Systematic Review

2008·

4citations

·D. Halpin

Journal of Medical Economics·

DOI

SymbioGBR: a web-based database of Symbiodinium associated with cnidarian hosts on the Great Barrier Reef

The SymbioGBR database provides a comprehensive overview of Symbiodinium diversity and host-associations on the Great Barrier Reef, aiding in classification and comparing host-Symbiodinium associations.

Rigorous Journal

2013·

55citations

·L. Tonk et al.

BMC Ecology·

DOI

Diversity and community structure of symbiotic dinoflagellates from Caribbean coral reefs

Symbiotic dinoflagellates in Caribbean coral reefs show diverse community structures, with a few types dominating the reef-wide distribution and numerous rare types showing high specificity for specific host species or genus.

Highly Cited

2002·

418citations

·T. Lajeunesse

Marine Biology·

DOI

A randomized open-label trial on the use of budesonide/formoterol (Symbicort®) as an alternative reliever medication for mild to moderate asthmatic attacks

Symbicort® and nebulized salbutamol both provide effective bronchodilation for mild to moderate asthmatic attacks, with no statistical difference in relief.

RCTRigorous Journal

2012·

9citations

·K. Chew et al.

International Journal of Emergency Medicine·

DOI

SYMBICORT® TURBUHALER®: A NEW CONCEPT IN ASTHMA MANAGEMENT

Symbicort®, a single inhaler containing budesonide and formoterol, is more effective and well-tolerated than separate inhalers for treating asthma, with a fast onset and convenient dosing schedule.

Rigorous Journal

2002·

13citations

·P. Kuna et al.

International Journal of Clinical Practice·

DOI

An evidence-based consensus for the classification of arbuscular mycorrhizal fungi (Glomeromycota)

This study proposes a consensus classification of arbuscular mycorrhizal fungi (Glomeromycota) based on molecular-phylogenetic evidence, rejecting some new names and synonymizing others.

Highly Cited

2013·

621citations

·D. Redecker et al.

Mycorrhiza·

DOI

A smarter way to manage asthma with a combination of a long-acting β2-agonist and inhaled corticosteroid

Symbicort SMART effectively manages asthma with a single inhaler, reducing exacerbations and requiring less corticosteroids, making it a more effective and simpler approach for patients.

Rigorous Journal

2007·

17citations

·O. Selroos

Therapeutics and Clinical Risk Management·

DOI

SymPortal: A novel analytical framework and platform for coral algal symbiont next‐generation sequencing ITS2 profiling

SymPortal is a novel analytical framework and platform for genetically resolving coral algal symbionts using next-generation sequencing data, enabling more accurate classification of global Symbiodiniaceae diversity.

Rigorous JournalHighly Cited

2019·

289citations

·B. Hume et al.

Molecular Ecology Resources·

DOI

Comparing clinical efficacy of Symbicort versus Pulmicort in reducing asthma symptom and improving its control

Symbicort 160/4.5 mg/inhalation has higher efficacy in reducing asthma symptoms and improving asthma control compared to low doses and Pulmicort.

RCTRigorous Journal

2014·

2citations

·M. Emami et al.

Advanced Biomedical Research·

DOI

The whole story: treatment outcomes with Symbicort.

Symbicort, a single inhaler containing budesonide and formoterol, provides better asthma control and is more cost-effective than budesonide alone, with reduced exacerbations and improved patient quality of life.

2002·

5citations

·R. ZETTERSTRM’ et al.

Respiratory medicine

Try another search

description of genetic engineering

crispr dangers

which is safer pantoprazole or omeprazole

proventil drug class

how far to space

whats our solar system called